AbbVie Inc. [NYSE: ABBV] gained 1.34% or 1.43 points to close at $108.22 with a heavy trading volume of 9029091 shares. The company report on March 31, 2021 that AbbVie to Host First-Quarter 2021 Earnings Conference Call.
AbbVie (NYSE: ABBV) will announce its first-quarter 2021 financial results on Friday, April 30, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
It opened the trading session at $106.88, the shares rose to $109.18 and dropped to $106.80, the range by which the price of stock traded the whole day. The daily chart for ABBV points out that the company has recorded 24.55% gains over the past six months. However, it is still -51.5% lower than its most recent low trading price.
If we look at the average trading volume of 7.47M shares, ABBV reached to a volume of 9029091 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AbbVie Inc. [ABBV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $122.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Bernstein have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 10, 2020. While these analysts kept the previous recommendation, Berenberg raised their target price to Hold. The new note on the price target was released on September 29, 2020, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another raise to $115, while Atlantic Equities analysts kept a Overweight rating on ABBV stock.
The Average True Range (ATR) for AbbVie Inc. is set at 2.28, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 4.09. The Price to Book ratio for the last quarter was 14.64, with the Price to Cash per share for the same quarter was set at 4.90. Price to Free Cash Flow for ABBV in the course of the last twelve months was 20.63 with Quick ratio for the last quarter at 0.70.
Trading performance analysis for ABBV stock
AbbVie Inc. [ABBV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.01. With this latest performance, ABBV shares gained by 0.34% in over the last four-week period, additionally plugging by 24.55% over the last 6 months – not to mention a rise of 42.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 55.74, with the RSI for the last a single of trading hit 59.74, and the three-weeks RSI is set at 54.08 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 106.55, while it was recorded at 106.32 for the last single week of trading, and 98.81 for the last 200 days.
AbbVie Inc. [ABBV]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +34.12 and a Gross Margin at +69.18. AbbVie Inc.’s Net Margin is presently recorded at +9.95.
Return on Total Capital for ABBV is now 19.65, given the latest momentum, and Return on Invested Capital for the company is 6.22. Return on Equity for this stock inclined to 185.81, with Return on Assets sitting at 3.80. When it comes to the capital structure of this company, AbbVie Inc. [ABBV] has a Total Debt to Total Equity ratio set at 665.82. Additionally, ABBV Total Debt to Total Capital is recorded at 86.94, with Total Debt to Total Assets ending up at 57.82. Long-Term Debt to Equity for the company is recorded at 599.46, with the Long-Term Debt to Total Capital now at 78.28.
Reflecting on the efficiency of the workforce at the company, AbbVie Inc. [ABBV] managed to generate an average of $96,936 per employee. Receivables Turnover for the company is 6.43 with a Total Asset Turnover recorded at a value of 0.38.AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.80.
AbbVie Inc. [ABBV]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, AbbVie Inc. posted 2.42/share EPS, while the average EPS was predicted by analysts to be reported at 2.25/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to 4.77%.
An analysis of insider ownership at AbbVie Inc. [ABBV]
There are presently around $129,486 million, or 69.70% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 142,563,074, which is approximately -1.228% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 124,423,484 shares of the stock with an approximate value of $13.47 billion in ABBV stocks shares; and STATE STREET CORP, currently with $8.46 billion in ABBV stock with ownership of nearly -0.059% of the company’s market capitalization.
Positions in AbbVie Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 1,432 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 59,642,771 shares. Additionally, 973 investors decreased positions by around 75,052,821 shares, while 265 investors held positions by with 1,061,806,979 shares. The mentioned changes placed institutional holdings at 1,196,502,571 shares, according to the latest SEC report filing. ABBV stock had 324 new institutional investments in for a total of 10,951,624 shares, while 90 institutional investors sold positions of 2,389,738 shares during the same period.